Overview

A Study of LY4268989 (MORF-057) in Healthy Participants

Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants
Phase:
PHASE1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Midazolam